Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04206813




Registration number
NCT04206813
Ethics application status
Date submitted
15/12/2019
Date registered
20/12/2019

Titles & IDs
Public title
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
Scientific title
An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination Regimen Over 6 Months Among Women Aged 16 to 45 Years Old, An Exploratory Immunogenicity Study
Secondary ID [1] 0 0
H-39051
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HPV Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Gardasil 9 2 dose regimen
Treatment: Drugs - Gardasil 9 3 dose regimen
Treatment: Drugs - Gardasil 9 rescue dose

Experimental: Intervention group - 240 eligible women will receive a 2-dose regimen of Gardasil 9 at (0 and 6 months, followed by a rescue 3rd dose at month 12)

Active comparator: Control group - 120 eligible women will receive the standard 3-dose regimen of Gardasil 9 at (0, 2, 6 months)


Treatment: Drugs: Gardasil 9 2 dose regimen
a 2-dose regimen of Gardasil 9 at 0 and 6 months

Treatment: Drugs: Gardasil 9 3 dose regimen
standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months

Treatment: Drugs: Gardasil 9 rescue dose
A rescue dose of Gardasil 9 will be given at 12 months
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in immunogenicity of Gardasil 9
Timepoint [1] 0 0
baseline and 7 months
Primary outcome [2] 0 0
Change in geometric mean titers ratios
Timepoint [2] 0 0
baseline and 7 months
Secondary outcome [1] 0 0
Number of participants with HPV seropositivity at day 1
Timepoint [1] 0 0
day 1
Secondary outcome [2] 0 0
Number of participants with HPV seropositivity at month 7
Timepoint [2] 0 0
month 7

Eligibility
Key inclusion criteria
* Women receiving care at Boston Medical Center
Minimum age
16 Years
Maximum age
45 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Currently pregnant
* Prior HPV vaccination
* A history of severe allergic reaction, including known allergy to any vaccine component, specially severe allergic to yeast
* Immunocompromised/previous immunosuppressive therapy
* Thrombocytopenia or other coagulation disorder
* Currently breastfeeding

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2025
Actual
Sample size
Target
360
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Massachusetts

Funding & Sponsors
Primary sponsor type
Other
Name
Boston Medical Center
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Natalie Joseph, MD MPH
Address 0 0
Boston Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Natalie Joseph, MD MPH
Address 0 0
Country 0 0
Phone 0 0
617-414-4524
Fax 0 0
Email 0 0
natalie.pierre-joseph@bmc.org
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04206813